Conduit Pharmaceuticals Set To Join Russell 3000 Index At Market Open On July 1, 2024
$CDT
Biotechnology: Pharmaceutical Preparations
Health Care
Conduit Pharmaceuticals Set To Join Russell 3000 Index At Market Open On July 1, 2024
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
8-K - CDT Equity Inc. (0001896212) (Filer)
8-K - CDT Equity Inc. (0001896212) (Filer)
8-K - CDT Equity Inc. (0001896212) (Filer)
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced the filing of two new patent applications that further expand the Company's intellectual property portfolio surrounding tapinarof, a drug currently approved for the treatment of psoriasis and atopic dermatitis. The first newly filed patent covers a combination therapy pairing tapinarof with a class of drugs clinically proven in psoriasis and atopic dermatitis, while the second patent relates to novel cocrystal forms of tapinarof with these agents. CDT believes these developments may underpin a second-generation tapinarof product with enhance
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") announces that its board of directors has approved a 1-for-25 reverse stock split of the Company's common stock. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios. The reverse stock split will become effective on March 26, 2026, at 5:00 pm, Eastern Time (the "Effective Time"), and the Company's common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market ("Nasdaq") at market open under the existing
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 23, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announces that it has completed initial signature mapping of its asset portfolio against Sarborg Limited's recently curated rare disease database, identifying multiple high-potential opportunities across a range of rare and underserved indications. The analysis, conducted using Sarborg's proprietary AI Signature Agent platform, evaluated CDT's portfolio of assets, including its solid-form patent portfolio and its licensed AstraZeneca compounds AZD1656 and AZD5658, against a database of approximately 1,700 rare disease signatures. The Company reports t
4 - CDT Equity Inc. (0001896212) (Issuer)
4 - CDT Equity Inc. (0001896212) (Issuer)
4 - CDT Equity Inc. (0001896212) (Issuer)
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has entered into a strategic transaction to acquire a 20% equity stake in Sarborg Limited ("Sarborg"), an agentic AI signature intelligence business operating across multiple industrial sectors. The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT's clinical assets through Sarborg's proprietary signature analysis and artificial intelligence capabilities. Sarborg's business is built on the principle that biological, chemical and industrial signatures
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced the acquisition of 9.25648743 Bitcoin ("BTC") for an aggregate purchase price of $1,005,000 (gross of fees), at an average acquisition price of $108,301.75 per BTC. Following this transaction, CDT's total Bitcoin holdings now stand at 17.9090111 BTC. This acquisition marks a continued execution of CDT's cryptocurrency treasury reserve strategy, aimed at diversifying the Company's balance sheet and enhancing long-term shareholder value through the prudent accumulation of digital assets. "CDT remains committed to strategically deploying capita
Includes Conduit's first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company") today announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company's first patent filings for AZD5658. These filings represent a significant expansion of Conduit's intellectual property portfolio, further supporting its strategy to advance and license differentiated, IP
SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
SC 13G - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, today announces the appointment of Simon Fry to its Board of Directors. Mr. Fry has over 30 years' experience in investment banking having held senior executive positions at various top-tier in
SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) (the "Company" or "Conduit"), today announced the Company is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday, May 24th, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automat
Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit's commitment to strengthening and broadening its intellectual property portfolio through solid-form technology to maximize future value SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced the appointment of Dr. Joanne Holland as Chief Scientific Officer. Dr. Holland brings over 20 years of experience to the CSO role at Conduit, having amassed expertise across the entire development spectrum. This includes a deep knowledge base in ide